ZOMETA® Case Study: How To Use ZOMETA For Treatment Of SREs In Breast Cancer

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Patient Case Study: Breast Cancer

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETAŽ Breast Cancer Patient Case Study - Marta

Marta N.

Aged 57 years
Math teacher
Grandmother of 2

Page

1 2 3 4

The vicious cycle of bone destruction is ongoing in patients like Marta

Osteoclasts and osteoblasts continually weaken bone in a vicious cycle of destruction^8,9

Because bone is constantly being attacked even when the primary tumor is in remission, ZOMETA^® must be dosed every 3 to 4 weeks8,10

ZOMETA®: Osteoclasts and osteoblasts continually weaken bone in SREs

Page

1 2 3 4

Because bone is constantly being attacked even when the primary tumor is in remission, ZOMETA must be dosed every 3 to 4 weeks^8,10

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

The vicious cycle of bone destruction is ongoing in patients like Marta

Because bone is constantly being attacked even when the primary tumor is in remission, ZOMETA® must be dosed every 3 to 4 weeks8,10

Because bone is constantly being attacked even when the primary tumor is in remission, ZOMETA must be dosed every 3 to 4 weeks8,10

Because bone is constantly being attacked even when the primary tumor is in remission, ZOMETA^® must be dosed every 3 to 4 weeks8,10

Because bone is constantly being attacked even when the primary tumor is in remission, ZOMETA must be dosed every 3 to 4 weeks^8,10